Tango Therapeutics-2026-JPM.pdf

《Tango Therapeutics-2026-JPM.pdf》由会员分享，可在线阅读，更多相关《Tango Therapeutics-2026-JPM.pdf（24页珍藏版）》请在三个皮匠报告上搜索。

1、The next wave of targeted therapies in oncologyJP Morgan Healthcare ConferenceJanuary 12,2026Disclaimer and safe harbor statementCertain statements in this presentation may be considered forward-looking statements.Forward-looking statements generally relate to future events,Tangos future financial a

2、nd operating performance,goals,expectations,beliefs,development plans,as well as development and clinical trial objectives for Tangos product pipeline(as individual therapies and combination therapies with other partys drugs).In some cases,you can identify forward-looking statements by terminology s

3、uch as“may”,“should”,“expect”,“intend”,“will”,“path”,“achievable”,“milestones”,“goal”,“forecast”,“estimate”,“potential”,“anticipate”,“believe”,“predict”,or“continue”,or the negatives of these terms or variations of them or similar terminology.For example,express or implied statements concerning the

4、following include or constitute forward-looking statements:the potential for the Company to have best-in-class oral PRMT5 inhibitors;the Companys belief that it has a significant opportunity to treat multiple common cancers;the Companys expected cash runway into 2028;the potential for vopimetostat t

5、o have best-in-class tolerability;the Companys expectations regarding its PRMT5 inhibitors as compared to competitor molecules,including in terms of safety and tolerability;the anticipated milestones and timing for the Companys drug programs(including registrational studies),including the timing for

6、 clinical trial initiation,enrollment,patient dosing,dose escalation,dose expansion,and clinicalupdates;of initial,interim,and final safety and efficacy or clinical activity data and results from clinical trial(s);the Companys expectations regarding a registrational trial for vopimetostat;the Compan